Latest T-cell lymphoma Stories
ResearchMoz.us includes new market research report "Peripheral T-Cell Lymphomas PTCL Clinical Trials Review, H1, 2014" to its huge collection of research reports.
Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC
Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh,
NK/T-cell lymphoma is a very aggressive form of cancer, and currently has no effective treatment along with having a poor prognosis. This subtype of lymphoma is pretty rare in the United States, but is responsible for a large number of deaths in Asia, particularly China and Korea.
WHITE PLAINS, N.Y., July 11, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is taking an aggressive and proactive approach to tackling the challenge of improving outcomes for cancer patients with particularly urgent needs.
NEW YORK, Sept. 21 /PRNewswire/ -- While general awareness of lymphoma remains high, a new survey released today by the Lymphoma Research Foundation (LRF) reveals significant knowledge gaps among Americans about the disease, which is the most prevalent form of blood cancer in the United States.
PHILADELPHIA, Sept. 14 /PRNewswire/ -- TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4Â®) in peripheral T-cell Lymphoma (PTCL) were published in the British Journal of Haematology (Sep 2010: 150(5):565-73).
WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July 27 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and Shape Pharmaceuticals announced today that they have entered into a partnership to advance Shape's novel, topical treatment for cutaneous T-Cell lymphoma (CTCL) into clinical development.
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.